Laboratory recognized for meeting highest international regulatory, safety standards
Princeton, N.J. — Covance Inc.(NYSE: CVD), a market leader in nutritional testing and food safety, announced today that the International Organization for Standardization (ISO) awarded full 17025 accreditation to its new microbiology laboratory in Madison, Wis. Covance acquired the laboratory from TRAC Microbiology in September 2011.
Granted by the American Association for Laboratory Accreditation, ISO accreditation confirms compliance with AOAC INTERNATIONAL guidelines for laboratories performing microbiological and chemical analyses of food and pharmaceuticals.
“This accreditation is a clear indication of Covance’s growing capabilities in providing leading microbiology services that meet or exceed industry standards of testing and quality,” said Marlo Vasquez, Vice President and General Manager, Covance Nutritional Chemistry and Food Safety. “Our team is well known for its dedication to ensuring the safety of our clients’ products. This accreditation represents the fourth Covance nutritional chemistry and food safety laboratory site to earn ISO accreditation and further demonstrates our commitment to excellence in operations and client service.”
This milestone follows successful ISO 17025 accreditation of the company’s laboratories in Battle Creek, Mich. (2011), Madison, Wis. (2009) and Singapore (2008). With nutritional testing services dating back more than 75 years, Covance plays a leading role in the design of testing programs required for nutrition facts labeling regulations and scientific standards.
About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services and food testing companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide. Information on Covance’s products and services, recent press releases, and SEC filings can be obtained through its website at http://www.covance.com.
Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company’s business are based largely on management’s expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company’s ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company’s ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company’s expectations.
